Brooks Laboratories Ltd vs Fabino Enterprises Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Brooks Laboratories Ltd is ₹ 56.48 as of 30 Apr 15:30 . The P/E Ratio of Brooks Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Fabino Enterprises Ltd changed from 600 on March 2023 to 84.5 on March 2025 . This represents a CAGR of -47.97% over 3 years The Market Cap of Brooks Laboratories Ltd changed from ₹ 153.53 crore on March 2021 to ₹ 317.37 crore on March 2025 . This represents a CAGR of 15.63% over 5 yearsThe Market Cap of Fabino Enterprises Ltd changed from ₹ 6.3 crore on March 2023 to ₹ 5.15 crore on March 2025 . This represents a CAGR of -6.50% over 3 years The revenue of Brooks Laboratories Ltd for the Dec '25 is ₹ 21.89 crore as compare to the Sep '25 revenue of ₹ 29.58 crore. This represent the decline of -26% The revenue of Fabino Enterprises Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Brooks Laboratories Ltd for the Dec '25 is ₹ 6.05 crore as compare to the Sep '25 ebitda of ₹ 8.65 crore. This represent the decline of -30.06% The ebitda of Fabino Enterprises Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Brooks Laboratories Ltd changed from ₹ -2.41 crore to ₹ 5.5 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Fabino Enterprises Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Brooks Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Fabino Enterprises Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Brooks Laboratories Ltd

Brooks Laboratories Limited was incorporated on January 23, 2002.
The company was initially promoted for manufacturing latest molecules in Injectables, tablets and dry syrups for the domestic customers.
The Company is a pharmaceutical manufacturing company working on contract basis and have its own marketing team to cater the critical care segment.
It offer a variety of dosage from Beta lactam Tablets, Beta lactam Dry Syrup, General Injections, Liquid Injections, Dry Powder Injections, and Eye/Ear Drops, Oncology Products, Hormonal Injections etc. The company's manufacturing facilities are designed to manufacture a variety of products in the formulation segment using a combination of processes.
At Baddi, they manufacture wide range of products under the formulation segment for various top notch companies of India.

About Fabino Enterprises Ltd

Fabino Enterprises Limited is a growing pharmaceutical company promoted by Atul Kumar Jain.
The Company was incorporated as 'Fabino Life Sciences Private Limited' on October 27, 2011 with the Registrar of Companies, Delhi and Haryana.
Subsequently, the Company got converted to Public Limited Company and the name of Company was changed to 'Fabino Life Sciences Limited'.
A fresh Certificate of Incorporation was issued on March 21, 2015 by the Registrar of Companies, Delhi. The Company operate in the business of manufacturing, marketing of pharmaceutical, allopathic, herbal, veterinary, and other consumer products like, packing, trading, etc.
The core business is marketing of pharmaceutical formulation & products in domestic market through its own distribution network and sales force under own brand name, getting Ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

FAQs for the comparison of Brooks Laboratories Ltd and Fabino Enterprises Ltd

Which company has a larger market capitalization, Brooks Laboratories Ltd or Fabino Enterprises Ltd?

Market cap of Brooks Laboratories Ltd is 166 Cr while Market cap of Fabino Enterprises Ltd is 4 Cr

What are the key factors driving the stock performance of Brooks Laboratories Ltd and Fabino Enterprises Ltd?

The stock performance of Brooks Laboratories Ltd and Fabino Enterprises Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Brooks Laboratories Ltd and Fabino Enterprises Ltd?

As of May 3, 2026, the Brooks Laboratories Ltd stock price is INR ₹56.48. On the other hand, Fabino Enterprises Ltd stock price is INR ₹20.31.

How do dividend payouts of Brooks Laboratories Ltd and Fabino Enterprises Ltd compare?

To compare the dividend payouts of Brooks Laboratories Ltd and Fabino Enterprises Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.